- Home
- MFA vs TNGX Comparison
MFA vs TNGX Comparison
Compare MFA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- TNGX
- Stock Information
- Founded
- MFA 1997
- TNGX 2014
- Country
- MFA United States
- TNGX United States
- Employees
- MFA N/A
- TNGX N/A
- Industry
- MFA Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- TNGX Health Care
- Exchange
- MFA Nasdaq
- TNGX Nasdaq
- Market Cap
- MFA 930.2M
- TNGX 1.0B
- IPO Year
- MFA N/A
- TNGX N/A
- Fundamental
- Price
- MFA $8.98
- TNGX $8.04
- Analyst Decision
- MFA Buy
- TNGX Strong Buy
- Analyst Count
- MFA 7
- TNGX 6
- Target Price
- MFA $11.00
- TNGX $10.80
- AVG Volume (30 Days)
- MFA 1.1M
- TNGX 4.4M
- Earning Date
- MFA 11-06-2025
- TNGX 11-04-2025
- Dividend Yield
- MFA 16.05%
- TNGX N/A
- EPS Growth
- MFA N/A
- TNGX N/A
- EPS
- MFA 0.86
- TNGX N/A
- Revenue
- MFA $274,911,000.00
- TNGX $66,501,000.00
- Revenue This Year
- MFA N/A
- TNGX $20.41
- Revenue Next Year
- MFA $14.85
- TNGX N/A
- P/E Ratio
- MFA $10.43
- TNGX N/A
- Revenue Growth
- MFA N/A
- TNGX 53.29
- 52 Week Low
- MFA $7.85
- TNGX $1.03
- 52 Week High
- MFA $12.60
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- MFA 42.09
- TNGX 50.66
- Support Level
- MFA $8.80
- TNGX $7.12
- Resistance Level
- MFA $9.26
- TNGX $8.17
- Average True Range (ATR)
- MFA 0.17
- TNGX 0.71
- MACD
- MFA 0.02
- TNGX -0.09
- Stochastic Oscillator
- MFA 35.87
- TNGX 49.07
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.